Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating income | -$7.55M | -$8.32M | -$16.6M | -$12.0M |
| Net income | -$7.58M | -$10.5M | -$16.3M | -$11.6M |
| EPS (diluted) | -$2.22 | -$1.38 | -$29.24 | -$8.56 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$5.48M | -$7.21M | -$15.2M | -$9.23M |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $1.31M | $8.56M | $2.59M | $11.9M |
| Total assets | $1.76M | $17.3M | $4.78M | $14.1M |
| Total liabilities | $6.86M | $4.13M | $1.86M | $2.23M |
| Shareholders' equity | -$15.1M | $13.2M | $2.92M | $11.9M |
| Retained earnings | -$38.7M | -$50.5M | -$66.8M | -$78.4M |
| Shares (wtd avg diluted) | 3.41M | 8.62M | 556K | 1.36M |
Every figure is extracted from INTENSITY THERAPEUTICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.